Navigation Links
Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott
Date:1/6/2009

WHIPPANY, N.J., Jan. 6, /PRNewswire/ -- Halo Pharmaceutical, Inc., a privately held specialty pharmaceutical company, has announced today the completion of its acquisition of the Whippany-NJ Manufacturing and Research facility from Abbott (NYSE: ABT). At over 200,000 square feet, Halo's facilities encompasses highly-diverse manufacturing and warehousing capabilities, including an impressive array of formulation services, operations for the aseptic filling of topical ointments, solid dosage forms (tablets and capsules), liquids, suppositories, associated packaging (tablet, powder, liquids and HUD) and ample laboratory space for formulation development, pre-clinical and clinical supplies and support of commercial operations. An additional asset is the site's capability to manufacture controlled substances (C2-C5) and an API manufacturing unit with an outstanding track-record of meeting DEA requirements. "We are extremely excited about the acquisition of this outstanding facility," said Douglas Kollmorgen, President of Halo Pharmaceutical. "The facility and the people who are continuing on with Halo, have a long and proud history here. Under the management of Abbott, the Whippany facility has been an exemplary production operation. We welcome the opportunity to continue that tradition of excellence for our customers going forward."

Halo's initial complement of personnel will consist of close to 80 highly-experienced pharmaceutical industry veterans from Abbott, and is expected to grow rapidly as the business develops further. "We are combining the best elements of traditional pharma with the innovation, agility and strong work ethic of a startup company," said Mohd Asif, Chief Financial Officer and head of the transaction team. "One of our great differentiators will be our focus on infusing the operation with our own unique culture, while preserving the focus on product quality, customer service and regulatory compliance." On the subject of the facility's heritage, Mr. Asif also explained that "it is essential that we recognize the significant contribution that has been made by Abbott in helping to smooth the transition of the Whippany facility to Halo stewardship, and to continue the strong legacy of this plant and its people."

A cornerstone of Halo's plan for success in a competitive environment will be a considerable focus on product quality, customer service and regulatory compliance. "This is a rare opportunity to build off the successes of a great company like Abbott," said John C. (Jack) Garvey, Vice President, Quality. "The compliance record of the Whippany site has been exemplary, and the culture is clearly focused on compliance. These important foundational elements will enable the creation of a systems approach to quality, with a focus on science-based, product-driven control frameworks that meet or exceed current FDA regulatory requirements and expectations."

Halo is currently seeking and evaluating opportunities for contract manufacturing, in-licensing, contract laboratory services, and the acquisition of branded products from companies looking to rationalize their product portfolios.

About Halo Pharmaceutical

Halo Pharmaceutical, headquartered in Whippany, NJ, is a full-service, specialty pharmaceutical company, offering state-of-the-art contract manufacturing, early stage formulation development and laboratory services to the pharmaceutical and related industries. Halo is currently a supplier of choice to a number of large and medium size brand pharmaceutical companies for important lifecycle products. Contract manufacturing capabilities include the ability to conduct aseptic filling, granulation, blending, tableting, coating, packaging and related warehousing operations. Halo Pharmaceutical is a privately-held company.


'/>"/>
SOURCE Halo Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CEVA Logistics Awarded Best 3PL Provider for Pharmaceutical, Chemical, HazMat and Fresh Food Supply Chains
2. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
3. Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008
4. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
5. China Sky One Medical, Inc. Closes Acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.
6. China Sky One Medical, Inc. to Acquire Heilongjiang Tianlong Pharmaceutical, Inc.
7. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
8. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
9. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
10. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... 03, 2016 , ... SELEX (systematic evolution of ligands ... random library of sequences depending on their attraction for a target molecule. These ... is commonly performed using filters, panning, or affinity chromatography separations. However, these traditional ...
(Date:5/3/2016)... ... , ... Elizabeth Murray has always loved walking one to two miles a ... shoulder and one on her arm. But she got to the point where she ... prolapse. , The valves of the heart wouldn’t close properly resulting in mitral regurgitation, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Diagnotes, ... by Tidelands Health, a three hospital system in South Carolina, to provide its ... lookout for technology that enhances communication, drives workflow efficiencies and improves provider and ...
(Date:5/3/2016)... ... May 03, 2016 , ... Each year, about 800,000 people suffer ... across the United States and account for one death every four minutes. Many ... permanently disabled. HCR ManorCare is launching a video series called “Your Brain,” in conjunction ...
(Date:5/3/2016)... ... May 03, 2016 , ... Intrigma, the ... that Legacy Health is expanding its use of Intrigma’s cloud-based physician scheduling solution, ... initial proof of concept. The Portland, Oregon based health system conducted a one-year ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... -- Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... Ireland 7.8 India 7.3, , Source: IMF and TechSci Research ... of Brazil , Russia , ... , registered the fastest GDP growth during the first decade of the ... recession in Brazil and Russia , ...
(Date:5/2/2016)... May 2, 2016  While nearly three-quarters of Americans ... have on their health, only about half report taking ... the results of a new survey announced today by ... start of National Osteoporosis Month, Hologic is raising awareness ... nearly 56 million Americans. Osteoporosis is a ...
(Date:5/2/2016)... SAN FRANCISCO , May 2, 2016 /PRNewswire/ ...  is expected to reach USD 11.1 billion by ... Grand View Research, Inc. Major drivers of the ... in therapeutic areas and government recommendations for periodic ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ...
Breaking Medicine Technology: